Therapeutic potential of galactosamine-modified hollow silica nanoparticle for improved drug targeting to liver cancer

Present state-of-the-art focusing on the formulates multifunctional hollow mesoporous silica nanoparticles (HMSNs) represent a reservoir for encapsulating warhead of active entail Nimbin (NB) into the hollow core and the surface modified by PEI-PLA by electrostatic interaction. The fabricated hollow mesoporous silica (HMSN) nano drug framework is amended with polyethyleneimine (PEI)-poly lactic acid (PLA) with carboxylic group terminus used to tag liver tumour-targeting agent galactosamine (GAL). Thus, with surface modified HMSNs capable of internalization into cancer cells, the ability of NB to discharge into cancerous cells influenced by environmental pH value. The emerging active ingredient firmly suppresses the expression of the P13/Akt pathway to induce apoptosis by creating DNA fragmentation, caspase activation and reactive oxygen species (ROS). The released NB drug significantly improves cancer cell killing in vitro. As a result, the analysis revealed a drug delivery platform by NB to understand the cancer cell targeting strategy.